^99mTc-Labeled LyP-1 for SPECT Imaging of Triple Negative Breast Cancer

Abstract

Triple negative breast cancer (TNBC), the most aggressive breast cancer type, is associated with high mortality and recurrence rates. An active-targeted strategy based on homing peptides is an effective approach to diagnose and treat cancer as it can deliver imaging agents or therapeutic drugs into desired tissues and accumulate less into off-target tissues. As a homing peptide, LyP-1 has shown properties of targeting, internalization, and proapoptosis to TNBC. In the study, we designed a Technetium-99m- (99mTc-) labeled LyP-1 and investigated its feasibility for targeted single-positron emission computed tomography (SPECT) imaging of TNBC. The results showed that the LyP-1 peptide had acceptable biocompatibility in the studied concentration range and could specifically bind to TNBC cells in vitro. 99mTc-labeled LyP-1 showed high radiochemical purity and stability and could be used as a probe for targeted SPECT imaging of TNBC cells in vitro and in a TNBC tumor-bearing mouse model. Our findings indicate that this active-targeted strategy has great potential to be developed into a new imaging tool for TNBC diagnosis.

LyP-1-Modified Multifunctional Dendrimers for Targeted Antitumor and Antimetastasis Therapy

“…Previously, we studied the imaging of 4T1 cells with technetium-99m ( 99m Tc)-labeled LyP-1 via SPECT, and the best T/M ratio in mice treated with 99m was 4.1. 35 In the present study, the best T/M ratio in mice treated with G5.NHAc-HPAO-131 I-(PEG-LyP-1) was 5.9, which was higher than the results reported previously. These data indicated that our multiple LyP-1 ligand-targeting nanosystems not only enhanced accumulation of 131 I-labeled NPs in tumors but also exhibited better targeting ability than a single LyP-1-based probe.…”

“…In the designed G5.NHAc-HPAO- 131 I-(PEG-LyP-1) dendrimers, the number of LyP-1-targeting peptide attached to each G5 dendrimer could be as high as 33.1, which is beneficial for the recognition of 4T1 tumors. Previously, we studied the imaging of 4T1 cells with technetium-99m ( 99m Tc)-labeled LyP-1 via SPECT, and the best T/M ratio in mice treated with 99m Tc-LyP-1 was 4.1 . In the present study, the best T/M ratio in mice treated with G5.NHAc-HPAO- 131 I-(PEG-LyP-1) was 5.9, which was higher than the results reported previously.…”

lncRNA HIF1A‑AS2: A potential oncogene in human cancers (Review)

“…Current treatments for TNBC include surgery, chemotherapy, radiotherapy and targeted therapy. However, the median overall survival rarely extends beyond 18 months in patients with advanced BC ( 29 ). Therefore, it is essential to study the molecular mechanism and identify novel biomarkers for management of TNBC.…”

99mTc-labeled iRGD for single-positron emission computed tomography imaging of triple-negative breast cancer

“…Therefore, achieving sensitive detection in the early TNBC stages continues to gain increased attention. One strategy is to develop novel diagnostic methods based on radionuclide molecular imaging that can provide accurate and sensitive detection of TNBC ( Liu et al, 2016 ; Song et al, 2019 ; Cavaliere et al, 2021 ).…”